Nektar Therapeutics (NKTR) Tops Q3 EPS by 18c
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $67.10 -1.84%
Revenue Growth %: -11.4%
Financial Fact:
License, collaboration and other: 8.37M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: -11.4%
Financial Fact:
License, collaboration and other: 8.37M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of ($0.06), $0.18 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $60 million versus the consensus estimate of $44.3 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Premarket movers: Xenon sinks on trial pause, Netflix hit by downgrade
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
